FDA Updates Plavix Label with PGx Data, but Does Not Provide Dosing Recommendations
June 17, 2009
FDA Updates Plavix Label with PGx Data, but Does Not Provide Dosing Recommendations
Without PGx-guided dosing information, it is unclear whether genetic testing to gauge Plavix response will go the same way as genetic testing for warfarin. At least one national insurer, Aetna, feels that the FDA did not provide enough information in the updated label to warrant coverage for the intervention.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Label Warns Against Plavix with CYP2C19 Inhibitors, Raises Questions about Role of Mutations
November 18, 2009 / Pharmacogenomics Reporter - FDA Official Says Vectibix/Erbitux Relabeling May Guide Sponsors on Agency's Criteria for Accepting Retrospective Data
October 7, 2009 / Pharmacogenomics Reporter - Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 4, 2012 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter